Article Text

Download PDFPDF
From bone biology to clinical outcome: state of the art and future perspectives
  1. Georg Schett1,
  2. Kenneth G Saag2,
  3. Johannes W J Bijlsma3
  1. 1Department of Internal Medicine 3, Erlangen, Germany
  2. 2Department of Rheumatology, University of Alabama, Alabama, USA
  3. 3Department of Rheumatology and Clinical Immunology, UMC Utrecht, The Netherlands
  1. Correspondence to Johannes W J Bijlsma, Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Box 85500, GA 3508, Utrecht, The Netherlands; j.w.j.bijlsma{at}


In the last decade progress has been made in our understanding of bone biology. In particular, the relation between inflammation and bone has become much clearer, leading to bone-targeting therapies in inflammatory rheumatic diseases. The clinical sequelae of the influences of both inflammation and immobility (due to arthritis) on bone for different rheumatic diseases (such as rheumatoid arthritis, systemic lupus erythematosus and spondyloarthritides) have also now captured the attention of clinicians. In the last decade the well-known negative influences of glucocorticoids on bone have become more treatable as a result of new drugs that stimulate osteoblasts and restore the negative bone balance.

Statistics from


  • Provenance and peer review Commissioned; externally peer reviewed.

  • Competing interests None.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.